Drug resistance in ERBB2 TMD/JMD mutants

Stable Identifier
R-HSA-9665737
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

With respect to pertuzumab, a therapeutic antibody that block ligand-driven heterodimerization of ERBB2, ERBB2 R678Q is sensitive to pertuzumab, while ERBB2 V659E, ERBB2 G660D, ERBB2 G660R and probably ERBB2 Q709L are resistant (Pahuja et al. 2018).

Literature References
PubMed ID Title Journal Year
30449325 Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations

Pahuja, KB, Nguyen, TT, Jaiswal, BS, Prabhash, K, Thaker, TM, Senger, K, Chaudhuri, S, Kljavin, NM, Antony, A, Phalke, S, Kumar, P, Mravic, M, Stawiski, EW, Vargas, D, Durinck, S, Gupta, R, Khanna-Gupta, A, Trabucco, SE, Sokol, ES, Hartmaier, RJ, Singh, A, Chougule, A, Trivedi, V, Dutt, A, Patil, V, Joshi, A, Noronha, V, Ziai, J, Banavali, SD, Ramprasad, V, DeGrado, WF, Bueno, R, Jura, N, Seshagiri, S

Cancer Cell 2018
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!